WO2024254589A3 - Products and compositions - Google Patents

Products and compositions Download PDF

Info

Publication number
WO2024254589A3
WO2024254589A3 PCT/US2024/033246 US2024033246W WO2024254589A3 WO 2024254589 A3 WO2024254589 A3 WO 2024254589A3 US 2024033246 W US2024033246 W US 2024033246W WO 2024254589 A3 WO2024254589 A3 WO 2024254589A3
Authority
WO
WIPO (PCT)
Prior art keywords
products
compositions
modulate
constructs
interfere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033246
Other languages
French (fr)
Other versions
WO2024254589A9 (en
WO2024254589A2 (en
Inventor
Dmitry Samarsky
Jack Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirnaomics Inc
Original Assignee
Sirnaomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirnaomics Inc filed Critical Sirnaomics Inc
Publication of WO2024254589A2 publication Critical patent/WO2024254589A2/en
Publication of WO2024254589A3 publication Critical patent/WO2024254589A3/en
Anticipated expiration legal-status Critical
Publication of WO2024254589A9 publication Critical patent/WO2024254589A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

Nucleic acid products that modulate, interfere with, or inhibit TMPRSS6 gene expression are provided, together with compositions containing the constructs and methods for their use.
PCT/US2024/033246 2023-06-09 2024-06-10 Products and compositions Ceased WO2024254589A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507408P 2023-06-09 2023-06-09
US63/507,408 2023-06-09

Publications (3)

Publication Number Publication Date
WO2024254589A2 WO2024254589A2 (en) 2024-12-12
WO2024254589A3 true WO2024254589A3 (en) 2025-05-30
WO2024254589A9 WO2024254589A9 (en) 2025-12-26

Family

ID=93796482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033246 Ceased WO2024254589A2 (en) 2023-06-09 2024-06-10 Products and compositions

Country Status (1)

Country Link
WO (1) WO2024254589A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140194489A1 (en) * 2011-03-29 2014-07-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of tmprss6 gene
US20210254076A1 (en) * 2013-05-22 2021-08-19 Alnylam Pharmaceuticals, Inc. TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140194489A1 (en) * 2011-03-29 2014-07-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of tmprss6 gene
US20210254076A1 (en) * 2013-05-22 2021-08-19 Alnylam Pharmaceuticals, Inc. TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
WO2024254589A9 (en) 2025-12-26
WO2024254589A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
WO2020117968A3 (en) Polymerases, compositions, and methods of use
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
EP4361261A3 (en) Novel cas13b orthologues crispr enzymes and systems
WO2020123887A3 (en) Novel crispr-cas systems for genome editing
WO2017027423A9 (en) Engineered crispr-cas9 compositions and methods of use
EP4471149A3 (en) Type v crispr-cas base editors and methods of use thereof
WO2017127807A8 (en) Crystal structure of crispr cpf1
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
WO2016205749A8 (en) Novel crispr enzymes and systems
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
WO2016148994A8 (en) A three-component crispr/cas complex system and uses thereof
WO2020086144A3 (en) APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
WO2017070633A3 (en) Evolved cas9 proteins for gene editing
EP3009511A3 (en) Novel crispr enzymes and systems
EP4552499A3 (en) Microbial consortia producing dipicolinic acid and methods for selecting microbes for co-formulation with carriers
WO2009036385A3 (en) Expression of nucleic acid sequences for production of biofuels and other products in algae and cyanobacteria
EP3983536A4 (en) Novel crispr dna targeting enzymes and systems
WO2019140102A8 (en) Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
WO2019079656A8 (en) Selective enrichment of a population of dna in a mixed dna sample through targeted suppression of dna amplification
WO2021247671A3 (en) Cell lines with multiple docks for gene insertion
WO2023250183A3 (en) Compositions and methods for epigenetic editing
WO2023081814A9 (en) Mobile elements and chimeric constructs thereof
WO2024081738A3 (en) Compositions, methods, and systems for dna modification
WO2024254589A3 (en) Products and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820223

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE